Al18F-NOTA-LM3 PET/CT in Patients With TIO

NCT07366099 · tracked via the Priya Life Science China tracker

Sponsor

Peking Union Medical College Hospital

Phase

Not applicable

Started

2023-03-30

Last updated

2026-01-26

Condition(s) studied

Tumor-Induced Osteomalacia

Investigational drug(s) / intervention(s)

Diagnostic Test: Al18F-NOTA-LM3Diagnostic Test: 68Ga-DOTATATE

Diagnostic Test: Al18F-NOTA-LM3: Al18F-NOTA-LM3 will be injected into the patients. Patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.

Diagnostic Test: 68Ga-DOTATATE: 68Ga-DOTATATE will be injected into the patients. Patients will undergo a whole-body PET/CT scan 40-60 minutes after injection.

Study summary

This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET/CT in patients with tumor-induced osteomalacia.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Patients aged 18 to 80 years. * Suspected or confirmed TIO patients. Exclusion Criteria: * Combined with other types of tumors. * Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min). * Pregnant or breast-feeding women. * Inability to perform PET/CT scans.

Primary outcome measure(s)

Diagnostic value — From study completion to 6 months after completion.
Sensitivity and specificity of Al18F-NOTA-LM3 PET/CT for TIO in comparison with 68Ga-DOTATATE PET/CT

Trial sites (1)

Facility	City	Region	Status
Peking Union Medical College Hospital	Beijing	Beijing Municipality	Recruiting

More Peking Union Medical College Hospital trials in China

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors Recruiting

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT Recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) Recruiting

An Observational Cohort Study to Obese Patients With Weight Cycling Active, not recruiting

A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated Balloon Alone in the Treatment of Chronic Femoropopliteal Artery Occlusions Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07366099 on ClinicalTrials.gov ↗ ← All trials in China